China’s Fosun to seek approval for BioNTech’s COVID-19 second vaccine, ends trials on first

BioNTech’s Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm’s coronavirus vaccine candidate that has completed early-stage trials in …
( read original story …)